by Dr. Stéphanie Durand-Panteix, CRIBL Lab CNRS7276/INSERM1262/University of Limoges, France
This webinar highlights the potency of 212Pb-alpha radioimmunotherapy in Multiple Myeloma treatment. The results of this study showed the efficacy of 212Pb-daratumumab in xenografted mice with significant tumor regression and increased survival. To conduct this preclinical study, we performed in vivo biodistribution study using USPECT4CT. Results obtained by whole-body SPECT/CT images using 203Pb, a gamma-emitter, allowed to consider a theranostic approach for 212Pb alpha-therapy with a chemically identical radioelement.
Took place: October, 2020
Duwboot 7a
3991 CD Houten
The Netherlands
Phone: +31 85 088 5753
Fax: +31 88 756 0094
E-mail: [email protected]
REQUEST MORE INFORMATION
MILabs products are used in more than 65 countries and are supported by a global network of distributors and factory trained support engineers.
Please contact MILabs directly for more information about your local MILabs business partner.